All In Biotech

Drug Trial Radar · NCT05686629

An Efficacy and Safety Study of Jaktinib Hydrochloride Tablets in the Treatment of Severe Novel Coronavirus Pneumonia

A Study to Assess the Efficacy and Safety of Jaktinib Hydrochloride Tablets in the Treatment of Severe Novel Coronavirus Pneumonia

Last checked: Nov 19, 2026Latest source record: Oct 24, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

120

Planned (sponsor's estimate)

Start

Apr 2024

Primary completion

Feb 2025

Study completion Mar 2025

Sponsor

Sponsor type
Industry
First posted
Jan 17, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study adopts a randomized, double-blind, placebo parallel control design, and is expected to include 120 eligible patients with severe novel coronavirus pneumonia.

Conditions

  • Novel COVID-19-Infected Pneumonia

Interventions

  • Jaktinib hydrochloride tabletsDrug

    2 doses per day, each containing two 50mg Jaktinib or placebo tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy of JaktinibTime frame: 14 days after randomization
  2. Efficacy of JaktinibTime frame: 28 days after randomization
  3. Efficacy of JaktinibTime frame: 28 days after randomization
  4. Efficacy of JaktinibTime frame: 28 days after randomization
  5. Efficacy of JaktinibTime frame: up to 28 days after randomization
  6. Time interval from randomization to dischargeTime frame: up to 28 days after randomization
  7. Efficacy of JaktinibTime frame: 28 days after randomization
  8. Efficacy of JaktinibTime frame: 28 days after randomization

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • West China Hospital Sichuan University

    Chengdu, Sichuan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.